Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSD

SAN JOSE, Calif., April 24, 2024. Lykos Therapeutics (formerly MAPS Public Benefit Corporation) ( " Lykos " ), a company dedicated to transforming mental healthcare, announced the completion of a European Phase 2 study (MP18), an open-label, multicenter...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials